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ABSTRACT 
It has been known for a long time that B cells play a role in rheumatoid arthritis (RA). By production 
of autoantibodies, presentation of auto-antigens and by producing cytokines B cells may contribute to 
the pathogenesis of RA. In recent years it has been shown that anti-B cell therapy is a powerful tool in 
the treatment of RA. The aim of this thesis was to a) investigate the effect on B cell ontogeny 
following B cell depletion therapy, b) during B cell depletion therapy evaluate serological and 
humoral immune responses and finally, c) try to establish a connection between Epstein-Barr virus 
(EBV) infection, CD25+ B cells and outcome of B cell deletion therapy.  
In paper I we could show that in bone marrow of RA patients following anti-CD20 treatment with 
rituximab (RTX) IgD expressing naïve cells are depleted whereas immature and memory B cells 
where still detectable. However, the long-term effects clearly showed a reduction of memory B cells in 
bone marrow. The examination of rheumatoid factor (RF) production revealed that RFs decline short 
after treatment but returned to baseline levels concurrently with the IgD expressing B cells when 
patients where subjected to an additional course.  
In paper II the cellular and humoral immune responses were evaluated by immunisation of RA 
patients before or during RTX treatment with a protein vaccine against influenza and a pneumococcal 
polysaccharide vaccine. The results suggest that both cellular and humoral immune responses are 
affected in patients receiving RTX treatment and we therefore suggest that immunisation should be 
performed before RTX treatment. 
In paper III we investigate the effects of EBV on selected B cell subsets and how infection may affect 
the clinical response to RTX treatment. The phenotypical study showed that B cells are more mature 
in EBV infected patients and the CD25+ B cell subset was more mature as compared to the CD25- B 
cell population. The evaluation of clinical response to RTX treatment with regard to B cell subsets 
showed that non-responding EBV+ patients had a significantly larger CD25+ plasma cell population. 
When investigating the effects of EBV stimulation in vitro we found that the CD25+ B cell population 
developed into antibody-producing cells to a higher extent than did the corresponding CD25- B cell 
population.  
The results of our studies indicate that that B cells play an essential role in the pathogenesis of RA. 
During RTX treatment we suggest that the IgD expressing population may harbour the autoantibody 
producing B cells. We also claim that that there are subsets of B cells (i.e. CD25+ B cells) that may 
have significant impact on the pathogenesis of RA, and the clinical outcome following RTX treatment.  
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